Pharmaceutical - Immunologicals, Respiratory and Pulmonary


Popular Filters

Stallergenes and DBV Technologies collaborate in birch pollen allergy research


French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014


Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product


US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

Ares Life Sciences to acquire Albion Medical and its GREER Laboratories unit


Ares Life Sciences says it has signed a definitive agreement to acquire 100% of the share capital of…

Albion MedicalAres Life SciencesGREER LaboratoriesImmunologicalsMergers & AcquisitionsOralairPharmaceuticalRespiratory and PulmonaryStallergenes

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval


The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

ALK Abello partner Torii progresses Japanese development of Mitizax


Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner,…

ALK AbelloImmunologicalsMitizaxPharmaceuticalResearchRespiratory and PulmonaryTorii Pharma

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Back to top